<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Understanding the biologic behavior of a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> is a prerequisite for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> registration code assignment </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this report was to propose appropriate behavior codes of the International Classification of Disease <z:hpo ids='HP_0002664'>Oncology</z:hpo> 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-O3) to rare, yet pathologically interesting hematopoietic and <z:mpath ids='MPATH_404'>soft tissue tumors</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The Study Group for Hematopathology, the Bone and Soft Tissue Pathology Study Group, and the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registration Committee prepared the questionnaire containing provisional behavior codes of selected diseases </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In situ lesions of mantle cell and follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, dendritic cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with perivascular epithelioid cell differentiation (PEComa), not otherwise specified were classified as malignant (-/3) </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:mpath ids='MPATH_723'>fibromatosis</z:mpath> group, with the exception of lipofibromatosis, was proposed as benign (-/0) </plain></SENT>
<SENT sid="5" pm="."><plain>Lipofibromatosis and several diseases that belong to the PEComa group were proposed as uncertain malignant potential (-/1) </plain></SENT>
<SENT sid="6" pm="."><plain>For the hematologic and <z:mpath ids='MPATH_404'>soft tissue tumors</z:mpath>, 274 and 288 members of the Korean Society of Pathologists, respectively, provided opinions through questionnaire, and most responders showed agreement with the provisional behavior code proposed </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The determination of behavior codes for the <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare diseases</z:e> described in this study, especially those of the PEComa group or malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, could be viewed as impractical and premature, but this study provides the basis for future research on this topic </plain></SENT>
</text></document>